Metabolic modes of action of the statins in the hyperlipoproteinemias

Atherosclerosis

Volumn 141, Issue 2, 1998, Pages 203-207

  Aguilar Salinas, Carlos Alberto ^a   Barrett, Hugh ^b   Schonfeld, Gustav ^c  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^b UNIVERSITY OF WASHINGTON   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Inhibitors; Physiologic modes of action; Statins

Indexed keywords

ATORVASTATIN; COMPACTIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; SIMVASTATIN; STATIN;

CHOLESTEROL METABOLISM; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; ENZYME INHIBITION; HUMAN; HYPERLIPOPROTEINEMIA; METABOLIC REGULATION; PRIORITY JOURNAL; RADIOIODINATION; RECEPTOR UPREGULATION; REVIEW;

ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEINS B; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPOPROTEINEMIAS; LIPOPROTEINS; LIPOPROTEINS, LDL; LIPOPROTEINS, VLDL;

EID: 0032401570     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(98)00198-1     Document Type: Review

References (48)

1. Endo A. The discovery and development of HMG-CoA reductase inhibitors. J. Lipid Res. 33:1992;1569.
2. Brown M.S., Dana S.E., Goldstein J.L. Regulation of 3-hydroxy-3-methylglutaryl coenzime A reductase activity in human fibroblasts by lipoproteins. Proc Natl Acad Sci. 70:1973;2162.
3. Goldstein J.L., Brown M.S. Lipoprotein receptors, cholesterol metabolism and atherosclerosis. Arch Pathol. 99:1975;181.
4. Brown M.S., Goldstein J.L. Receptor-mediated control of cholesterol metabolism. Science. 191:1976;150.
5. a and ML-236B, fungal metabolites having hypocholesterolemic activity. FEBS Lett. 72:1976;323.
6. Brown M.S., Faust J.R., Goldstein J.L., Kaneko I., Endo A. Induction of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in human fibroblasts incubated with compactin (ML-236B), a competitive inhibitor of the reductase. J Biol Chem. 253:1978;1121.
7. Mabuchi H., Haba T., Tatami R., Miyamoto S., Sakai Y., Wakasugi T. et al. Effects of an inhibitor of 3-hydroxy-3-methylglutaryl coenzime A reductase on serum lipoproteins and ubiquinone-10 levels in patients with familial hypercholesterolemia. N Engl J Med. 305:1981;478.
8. Bilheimer D.W., Grundy S.M., Brown M.S., Goldstein J.L. Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes. Proc Natl Acad Sci USA. 80:1983;4124.
9. Malmandier C.L., Lonti J.F., Delcoix C., Magat T. Effect of simvastatin on receptor-dependent low density lipoprotein catabolism in normocholesterolemic human volunteers. Atherosclerosis. 80:1989;101.
10. Uauy R., Vega G.L., Grundy S.M., Bilheimer D.W. Lovastatin therapy in receptor-negative homozygous familial hypercholesterolemia: lack of effect on low-density lipoprotein concentration or turnover. J Pediatr. 113:1988;383.
11. Pedersen T.R., Kjekshus J., Berg K., Haghfelt T., Feergeman O., Thorgeirsson G. et al. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study. Lancet. 344:1994;1383.
12. Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., MacFarlane P.W. et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 333:1995;1301.
13. MAAS investigators. Effect of simvastatin on coronary atheroma: the multicentre Anti-Atheroma Study (MAAS). Lancet 1994;344:633-38.
14. Jukema J.W., Bruschle A.V., van Boven A.J., Reiber J.H., Bal E.T., Zwinderman A.H. et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation. 91:1995;2528.
15. Grundy S.M., Vega G.L. Influence of mevinolin on metabolism of low density lipoproteins in primary moderate hypercholesterolemia. J. Lipid Res. 26:1985;1464.
16. Arad Y., Ramakrishnan R., Ginsberg H. Lovastatin therapy reduces low density lipoprotein apo B levels in subjects with combined hyperlipidemia by reducing the production of apo B-containing lipoproteins: implications for the pathophysiology of apo B production. J Lipid Res. 30:1990;567.
17. Arad Y., Ramakrishnan R., Ginsberg H. Effects of lovastatin therapy on very low density lipoprotein triglyceride metabolism in subjects with combined hyperlipidemia: evidence for reduced assembly and secretion of triglyceride-rich lipoproteins. Metabolism. 41:1992;487.
18. Vega G.L., Grundy S.M. Lovastatin therapy in nephrotic hyperlipidemia: effects on lipoprotein metabolism. Kidney Int. 40:1988;129.
19. Parhofer K.G., Barret P.H.R., Dunn J., Schonfeld G. Effect of pravastatin on metabolic parameters of apolipoprotein B in patients with mixed hyperlipoproteinemia. Clin Invest. 71:1993;939.
20. Gaw A., Packard C.J., Murray E., Lindsay G.M., Griffin B.A., Caslake M.J. et al. Effects of simvastatin on apo B metabolism and LDL subfraction distribution. Arterioscler Thromb. 13:1993;170.
21. Vega G.L., Grundy S.M. Influence of lovastatin therapy on metabolism of low density lipoproteins in mixed hyperlipidemia. J Intern Med. 230:1991;341.
22. Huff M.W., Burnett J.R. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and hepatic apolipoprotein secretion. Curr Opin Lipidol. 8:1997;138-145.
23. Parhofer K.G., Barrett P.H.R., Bier D.M., Schonfeld G. Determination of the kinetic parameters of apolipoprotein B metabolism using amino acids labeled with stable isotopes. J Lipid Res. 32:1991;1311.
24. Barrett P.H.R., Foster D.M. Design and analysis of lipid tracer kinetic studies. Curr Opin Lipidol. 6:1996;143-148.
25. Aguilar-Salinas C.A., Barrett P.H.R., Kelber J., Delmez J., Schonfeld G. Physiologic mechanism of action of lovastatin in nephrotic syndrome. J Lipid Res. 36(1):1995;120-126.
26. Aguilar-Salinas C.A., Barrett P.H.R., Schonfeld G. Description of a kindred with familial combined hyperlipidemia with unusual kinetic abnormalities of the apolipoprotein B containing lipoproteins. Effects of pravastatin therapy. Arterioscler Thromb Vasc Biol. 17:1997;72-82.
27. Aguilar C.A., Barrett P.H.R., Parhofer K.G., Young S., Schonfeld G. Apolipoprotein B-100 production is decreased in subjects heterozygotes for truncations of apolipoprotein B. Arterioscler Thromb. 15(1):1995;40-45.
28. Venkatesan S., Cullen P., Pacy P., Halliday D., Scott J. Stable isotope show a direct relation between VLDL apo B overproduction and serum triglycerides levels and indicate a metabolically and biochemically coherent basis for familial combined hyperlipidemia. Arterioscler Thromb. 13:1993;1110.
29. Watts G.F., Cummings M.H., Umpleby M., Quiney J.R., Naumova R., Thompson G.R. et al. Simvastatin decreases the hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in heterozygous familial hypercholesterolemia: pathophysiological and therapeutic implications. Eur J Clin Invest. 25:1995;559-567.
30. Cortner J.A., Bennet M.J., Le N.A., Coates P.M. The effect of lovastatin on very low density lipoprotein apolipoprotein B production by the liver in familial combined hyperlipidemia. J Inher Metab Dis. 16:1993;127.
31. Couture P., Gaudet D., Brun D., Bergeron J., Cantin L., Black D. et al. Effect of atorvastatin on serum levels of lipoproteins in French Canadians with homozygous or compound heterozygous familial hypercholesterolemia. Atherosclerosis. 134:1997;54.
32. Raal F., Pilcher G., Illingworth R., Pappu A., Stein E., Laskarzewski P. et al. Expanded-dose simvastatin is effective in homozygous familial hypercholesterolemia. Atherosclerosis. 135:1997;249-256.
33. Marais A., Naumova R., Firth J., Penny C., Neuwirth C., Thompson G. Decreased production of low density lipoprotein by atorvastatin after apheresis in homozygous familial hypercholesterolemia. J Lipid Res. 39:1997;2071-2078.
34. Watts G.F. Inhibition of cholesterogenesis decreases hepatic secretion of apo B-100 in normolipidemic subjects. Am J Physiol. 273:1997;E462-E470.
35. Krul E.S., Kleinman Y., Kinoshita M., Pfleiger B., Oida K., Law A. et al. Regional specificities of monoclonal anti-human apolipoprotein B antibodies. J Lipid Res. 29:1988;937-947.
36. Innerarity T.L., Weisgraber K.H., Arnold K.S., Mahley R.W., Krauss R.M., Vega G.L. et al. Familial defective apolipoprotein B-100: low density lipoproteins with abnormal receptor binding. Proc Natl Acad Sci USA. 84:1987;6919-6923.
37. f 100-400 hypertriglyceridemic very low density lipoproteins by the low density lipoprotein receptor pathway in normal human fibroblasts. J Biol Chem. 258:1983;4526-4533.
38. Khan B.K., Wilcox H.G., Heimberg M. Cholesterol is required for secretion of very low density lipoprotein by rat liver. Biochem J. 259:1989;807.
39. Vance J.E., Vance D.E. Specific pools of phospholipids are used for lipoprotein secretion by cultured rat hepatocytes. J Biol Chem. 261:1986;4486-4491.
40. Riches R.M., Watts G.F., Naumova R.P., Kelly J.M., Croft K.D., Thompson G.R. Direct association between the hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 and plasma mevalonic acid and lathosterol concentrations in man. Atherosclerosis. 135:1997;83-91.
41. Thompson G.R., Naumova R.P., Watts G.F. Role of cholesterol in regulating apolipoprotein B secretion by the liver. J Lipid Res. 37:1996;439-447.
42. Burnett J.R., Wilcox L.J., Telford D.E., Kleinstiver S.J., Barrett P.H.R., Newton R.S. et al. Inhibition of HMG-CoA reductase by atorvastatin decreases both VLDL and LDL apolipoprotein B production in miniature pigs. Arterioscler Thromb Vasc Biol. 17:1997;2590-2600.
43. Naumova R.P., Marais Ad., Mountney J., Firth J.C., Rendell N.B., Taylor G.W. et al. Plasma mevalonic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMG-CoA reductase inhibitors in familial hypercholesterolemia. Atherosclerosis. 119:1996;203-213.
44. Benoist F., Grand-Perret T. Apo B-100 secretion by HepG2 cells is regulated by the rate of triglycerides biosynthesis but not by intracellular lipid pools. Arterioscler Thromb Vasc Biol. 16:1996;1229.
45. Cianflone K.M., Yasruel Z., Rodriguez M.A., Sniderman A.D. Regulation of apo B secretion from HepG2 cells: evidence for a critical role for cholesteryl ester synthesis in the response to a fatty acid challenge. J Lipid Res. 31:1990;2045-2055.
46. Park J.S., Lemieux S., Lewis G.F., Kuksis A., Steiner G. Chronic exogenous insulin and chronic carbohydrate supplementation increase de novo VLDL triglyceride fatty accid production in rats. J Lipid Res. 38:1997;2529-2536.
47. Naumova R.P., Marais A., Mountney J., Firth J.C., Rendell N.B., Taylor G.W. et al. Plasma mevalonic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMG-CoA reductase inhibitors in familial hypercholesterolemia. Atherosclerosis. 119:1996;203-213.
48. Cuchel M., Schaefer E.J., Millar J.S., JonesPeter J.H., Dolnikowski G.G., Vergani C. et al. Lovastatin decreases de novo cholesterol synthesis and LDL apo B-100 production rates in combined-huyperlipidemic males. Arterioscler Thromb Vasc Biol. 17:1997;1910-1917.